According to Li, there are two other VEGF-targeted drugs in late-stage clinical trials: Neovastat, developed by Aeterna Laboratories (nasdaq: AELA - news - people ), and Thalomid, better known as thalidomide, which is being tested by Celgene (nyse: CELG - news - people ).